RECENT NEWS

Molecular diagnostics firm Co-Diagnostics has announced that it has completed the assay development strategy for the Bundibugyo virus (BDBV) currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda.

SLAS, the Society of Laboratory Automation and Screening, welcomed 137 exhibitors and more than 1,500 registrants from more than 30 countries at its 2026 Europe Conference and Exhibition held in Vienna, Austria in May 2026.

Molecular diagnostics company Yourgene Health has launched its new Insight DPYD assay, an assay utilising genetic insights for safer chemotherapy treatments to align with updated testing guidelines.

A study led by researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has identified a mitochondrial ‘checkpoint’ that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumours.

The first UKHSA One Health report tracks vector-borne diseases in England, with Lyme disease remaining the most common infection in 2025.

The World Health Organization (WHO) has declared that the current outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency.

Leading infection specialty organisations across the UK have launched a new report calling for urgent action to support and strengthen and modernise the UK’s infection specialist workforce.

The Institute of Biomedical Science (IBMS) has published a new guidance document supporting the safe, ethical and transparent use of generative artificial intelligence (AI) across IBMS qualifications.

Creative data technology provider InterSystems has announced that its electronic health record (EHR) solutions have just become the first AI-native EHR to achieve EU MDR certification

The NHS Modernisation Bill brought forward in the UK Parliament on Thursday 14 May will introduce the Single Patient Record, allowing fragmented health information to be joined up around the country, and will cut layers of bureaucracy so more time and money can be spent on frontline services.

A new report published by the UK Health Security Agency (UKHSA) shows that the trend in HIV diagnoses in England have continued to fall, with England meeting the UNAIDS 95-95-95 targets again.

Hundreds of thousands of babies will be screened as part of a new NIHR-funded trial evaluating newborn screening for spinal muscular atrophy (SMA).

More than 1,500 people a year with an aggressive form of stomach cancer are set to receive a new treatment available on the NHS, after NICE recommended durvalumab - the first immunotherapy for people with this form of cancer.

Precision medicine firm SOPHiA GENETICS has announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the UK as part of NHS England's revolutionary ‘blood test-first' programme.

Cepheid has received CE marking under the in vitro medical device regulation (IVDR) for the Xpert GI Panel. This multiplex PCR test is designed to enable fast, accurate detection of 11 clinically relevant gastrointestinal (GI) pathogens from a single patient sample.

AstraZeneca and Roche Diagnostics Asia Pacific have signed a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets, a first in the region.

Northern Ireland’s rapidly growing life sciences industry is set to benefit from closer collaboration with the UK regulator, as the Medicines and Healthcare products Regulatory Agency (MHRA) has announced it is establishing a hub in Northern Ireland, hosted by Invest Northern Ireland in Belfast.

A novel blood test for identifying damage to the lining of microscopic blood vessels could transform the ability to detect heart and kidney disease at its very earliest stages, suggests new research.

Upfront Diagnostics has announced the commercial launch of LVOne, a rapid blood test designed to help identify large vessel occlusion (LVO) strokes in the pre-hospital setting. The test has received UKCA marking, enabling clinical use in the United Kingdom, and is now being deployed in partnership with London Ambulance Service (LAS).

Roche has received the CE mark for its Elecsys pTau217 blood test, designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease.